PROCESS FOR PREPARING HETEROGENIC PROTEIN

Abstract: A process for preparing a heterogenic protein by cultur­ ing a heterogenic protein-producing transformant obtained by gene-controlling technique and recovering a produced heterogenic protein, which process comprises removing an outer cell wall of the transformant containing the protein therein, and solublizing the protein with a salt dissociating at least one of chloride, thiocyanate, and nitrate ions. This pro­ cess makes it possible to recover the heterogenic protein in a high yield in the form showing an activity in bioassay.

Description: SPECIFICATION METHOD OF PRODUCING HETEROLOGOUS PROTEINS TECHNICAL FIELD AND DISCLOSURE OF THE INVENTION TECHNICAL FIELD This invention relates to a method of producing heterologous proteins by recovering heterologous proteins from transformants capable of producing heterologous proteins. as obtained by gene nanipulation techniques. BACKGROUND ART Recombinant DNA technology has made it possible to cause expression and production of heterologous proteins in bacteria and other hosts. For example, manj human proteins, including various types (a, 5, y) of human interferon (hereinafter, HIFN), urokinase and TPA (human tissue plasminogen activating factor), are produced in hosts by transforming the hosts with DNA. coding for these proteins and propagating the thus-obtained transformants under conditions suited for the expression of said heterologous proteins. However, heterologous proteins are often insolubilized and precipitate in hosts. In case the desired proteins form such precipitates, the recovery of these encounters the following problems.. First, it becomes necessary that those proteins which occur as precipitates in hosts should be separated from host substances and, in addition, solubilized. Second, desired proteins mostly occur in biologically inactive form. For solving these problems, the prior art has proposed a method comprising treatment with. a proteindenaturing agent (Japanese Kokai Tokkyo Koho 59-161321) and a method comprising treatment with hydrochloric acid-guanidine (USP 4476049). However, these methods are still unsatisfactory with respect to the recovery of desired proteins. DISCLOSURE OF THE INVEICIOtI It is an object of the present invention to provide a method of recovering heterologous proteins from genetically engineered. transformants in higher yields by solubilizing the heterologous proteins occurring as precipitates in said transformants to thereby restore the forms in which they are active in bioassays. The present invention thus provides a method of producing heterologous proteins by cultivating a genetically engineered transformant capable of producing a heterologous protein and recovering the thus-produced heterologous protein, which is characterized in that, in a step after removal of the outer cell wall frbm.the transformant with the heterologous protein produced contained therein, the heterologous protein is solubilized with at least one ion selected from among the chloride ion, thiocyanate ion and nitrate ion each derived from a dissociable salt. (a) Starting materials The starting materials.in the practice of the EDTA. Examples of the buffer are 10 mM phosphate buffer (pH 8.0) and 250 mM Tris-hydrochloride buffer (pH 8.0), among others. The transformant (cell) concentration is preferably such that the OD650 value amounts to .100-200. The cell wall poly & ccharide-digesting enzyme concentration, when the enzyme is lysozyme, for instance, is preferably adjusted to 0.1-1 mg/ml, and the chelatingagent concentration to 10-100 mM. The suspension period preferably amounts to' 10-60 minutes and the treatment temperature to 0 C # 3 C. Solubilization: The above suspension treatment is followed. by treatment with a salt which, upon dissociation, affords at least one ion selected from among the chloride ion, thiocyanate ion and nitrate ion. Generally, a buffer containing such salt is added. Preferred examples of the salt are alkali metal salts (sodium salts, potas sium salts, etc.) and alkaline earth metal salts (calcium salts, magnesium salts, etc.), which are ionically dissociable as mentioned above, and particularly preferred are alkaline earth metal -chlorides,, alkali,metal thiocyanates and alkali metal nitrates. Specifically, magnesium chloride, 'potassium. thiocyanate, sodium thiocyanate and sodium nitrate, among others, are suitable examples. The same buffer as mentioned above is used as the buffer. When the salt is a chloride. or nitrate ion-releasing ones the salt is added to a final concen tration of 0.15-6 M, preferably 0.25-3 M and, when the salt is a thiocyanate ion-releasing one, to a final concentration of 0.25-1.5 M, preferably 0.3-1.0 M. The: treatment is cÅarried¯out generally under conditions of about 10-60 minutes and about 0 C + 3 C. Desired proteins are thus solubilized. Recovery: The above-mentioned solubilization treatment is generally followed.by recovery of the heterologous proteins. Those techniques which are conventional for protein purification may be used suitably for the recovery. For instance, fractionation based on the solubility difference, such as fractionation with ammonium sulfate, fractionation with ethanol and fractionation with acrinol., and centrifugation are preferable. The fractionation wth ammonium sulfate is carried out by combining a fractionation step using a 10-20% quantity of saturated ammonium sulfate and a fractionation step using a 40-50% quantity ,of saturated ammonium sulfate. The centrifugation is carried out at 10,000-25,000 rpm for 10-60 minutes. The sediment is removed and the supernatant is recovered. Dialysis: Optionally, the fraction recovered is then dialyzed. On the occasion, of dialysis, a buffer (e.g. phosphate buffer) preferably having a pH of 6-8 and a concentration of 0.01-0.2 M is used for salt concentration adjustment. Preferably, the dialysis is performed for a period not shorter than 30 hours. High-degree purification: Various heterologous proteins can b purified to a high degree as desired by appropriate.means of fractionation selected for the respective heterologous proteins (preferably by affinity chromatography using monoclonal antibodies). Formulation: Preparations containing such highly purified heterologous proteins are produced by conventional methods per se known and selected depending on the purpose for which the respective preparations are produced. In the case of drug production. the proteins are subjected,. if desired,.to treatment for removal Qf microorganisms ,and for sterilization and then are made up into liquid or dry preparations following investigations. as to excipients,. 'stabilizers and solvents. The production met,hod,according to the invention is applicable to the production pf any heterologous proteins that can be produced in genetically engineered transformants, such as, for example, interferons (p(, # andr X, urokinase, HBsAg and TPA. The following working examples and experimental examples are given for the purpose of illustrating the present invention in more detail. Example 1 The Escherichia coli, strain W3110 carrying the plasmid PYS61 (Japanese Patent Application 59-229864) with a human interferon-y polypeptide-encoding DNA fragment inserted therein was cultivated overnight at 370C in LB + glucose medium (prepared by dissolving 0.63 gof Tris base, 10 g of polypeptone, 5 g of yeast extract, 5 g of wall, 1 g of glucose' and 20 mg of ampicillin in water to make one liter) and a 2-ml portion of the culture was used to inoculate 100 ml of KE-9 medium (prepared by dissolving 120 g of Na2HPO4, 60 g of NaH2PO4, 20 g of NaCl, 300 g of casamino acids and 50 g of yeast extract in water to make 10 liters). After cultivation at 370C for 1 hour, indoleacrylic acid, a tryptophan gene inducer, was added to 40 Vg/ml and, then, cultivation was further continued for 7-10 hours. Cells were harvested by centrifugation at 4,000 r.p.m. for 20 minutes and washed with 30 mM NaCl-50 mM Tris-hydrochloride buffer (pH 8.0). The cells thus washed were suspended in a lysing buffer [30 mM NaCl, 50 mM EDTA, 250 mM Tris-hydrochloride (pH 8.0), 10 g/ml PMSF (phenylmethylsulfonyl fluoride), 1 mg/ml BSA (bovine serum albumin), 0.25 mg/ml lysozyme] to a cell concentration of OD650 = 160, and the suspension was allowed to stand at 0 C for 30 minutes. Then, an equal volume of a buffer having the same composition as the above lysing buffer except that it was free of lysozyme but contained sodium nitrite in a concentration of 2 M was added, and the mixture was allowed to stand at 0 C for 30 minutes. The subsequent centrifugation at18,000 r.p.m. for 30 minutes gave a supernatant, which was dialyzed against 0.1 H KH2PO4 (pH 7.0) used as the dialyzing solution and then assayed for interferon-r (IFN-#) by the cpe inhibition method [Havell, E.A. and Vilcek, J., Antimicrob, Agents Chemother., vol. 2, pages 476-484 (19722] using, however, Sindbis virus as the virus and human amnion-derivedFL3-l cells as the animal cells], The results are shown in Table 1. In the control run, the lysozyme treatment was followed by two repeated freezingthawing cycles and then by assaying Table 1 IFN-# (IU/1) Control 1.8 x 108 Example 1 (NaNO3) 6.0 x 108 Example 2 The same bacterial strain as used in Example 1 was cultivated and cells were harvested and washed in the same manner as in Example 1. The cells (corresponding to 1.8 liters of culture broth) were divided into two equal portions and each portion was suspended in the lysing buffer in a cell concentration corresponding to OD650 = 160, and the suspension was allowed to stand at 0 C for 30 minutes. Then, an equal volume of a buffer having the same composition as the above lysing buffer except that it w"s free of lysozyme and contained magnesium chloride in a concentration of 1 M was added the mixture was allowed ; to stand at 0 C for 45 minutes. In the control run, the lysozyme treatment was followed by two repeated freezingthawing cycles. The subsequent l-hour centrifugation at 20,000 r.p.m. gave a supernatant, which was assayed for IFN-# by the cpe inhibition method. The results thus obtained are shown in Table 2. Table 2 IFN-# (IU/1) Control 2.9 x 108 Example 2 (Mg9I2) 9.3 x 10 Example 3 The Escherichia coli HB101 strain carrying the plasmid PYS6l (Japanese Patent Application 59-229864) was cultivated and cells were harvested and washed in the same manner as in Example 2. The cells (corresponding to 1.8 liters of culture broth) were divided into two equal portions and IFN-# was extracted in the same manner as in Example 2. The results thus obtained are shown in Table 3. Table 3 IFN-# (IU/1) Control 3.6 x 108 Example 3 (MgCl2) 9.4 x 108 Example 4 The TPA-producing Escherichia coli HB101 strain was cultivated and cells were harvested and washed in the same manner as in Example 1. The cells were suspended in the lysing buffer in a cell concentration of OD650 = 160, and the suspension was allowed to stand at 0 0C for 30 minutes. Then, an equal volume of a buffer having the same composition as the above lysing buffer except that it was free of lysozyme and contained sodium nitrate in a concentration of 2 M was added. The mixture was allowed to stand at 0 C for 45 minutes and then centrifuged at 18,000 r.p.m. for 30 minutes to give a supernatant. ss-Mercapto- ethanol was added to the supernatant to a final concentration of 30 mM and the mixture was allowed to stand at room temperature for 2 hours. The lysate was dialyzed against 500 volumes of dialyzing solution A [30 mM Nail, 10 mM EDTA, 50 mM Tris-hydrochloride (pH 8.0), 1 mM reduced form glutathione, 10% glycerol). Reduced form glutathione and oxidized form glutathione were added to the dialyzate in final concentrations of 10 mM and 1 mM, respectively, and the resultant solution was allowed to stand overnight at room temperature and then finally dialyzed against 500 volumes of dialyzing solution B E30 mM NaCl, 10 mM EDTA, 50 mM Tris-hydrochloride, 0.1 rdM reduced form glutathione]. The dialyzate was assayed for PA activity (piasminogen activator activity) by the fibrin plate metho4. The results thus obtained are shown in Table 4. As a result, an about 50-fold increase in PA activity was observed as compared with the control (two repeated freezing-thawing cycles following lysozyme treatment). Table 4 TPA (U/ml) Control 0.5 Example 4* (NaNO3) 1.8 Example 4** 27.0 * : The PA activity was measured after dialysis following sodium nitrate treatment. ** : The PA activity was measured after sodium nitrate treatment, ss-mercaptoethanol treatment and oxidation treatment in the GSH/GSSG-containing buffer. GSH means reduced form glutathione and GSSG oxidized form glutathione. Experimental Example 1 The effects of various salts added were comparatively examined by carrying out IFN-y extraction and recovery from the transformant in the same manner as in Example.l. The results obtained are summarized in Table 5. Each additive was added in lieu of sodium nitrate in Example 1 and, otherwise, the whole procedure was the same as in Example 1, The additives, addition levels and IFN-y activity data are shown in Table 5. ' I Table 5 'V. EMI12.1 <tb> <SEP> Final <tb> <SEP> Additive <SEP> concen- <SEP> I <SEP> F <SEP> N <SEP> - <SEP> # <SEP> (IU/1) <tb> <SEP> tration <tb> <SEP> Control <SEP> 1.8 <SEP> x <SEP> 108 <tb> MgCl2 <SEP> 0.1 <SEP> 1.2 <SEP> x <SEP> 108 <tb> <SEP> 0.25 <SEP> 5.5 <SEP> x <SEP> 108 <SEP> <tb> <SEP> 0.5 <SEP> 9.4 <SEP> x <SEP> 108 <SEP> <tb> <SEP> 2 <SEP> 5.8 <SEP> x <SEP> 108 <tb> <SEP> 5 <SEP> 4.8 <SEP> x <SEP> 10' <tb> <SEP> NaNO3 <SEP> 0.1 <SEP> 1.O <SEP> x <SEP> 108 <tb> <SEP> 0.25 <SEP> 4.3 <SEP> x <SEP> 10' <tb> <SEP> 0.5 <SEP> 4.4 <SEP> x <SEP> 108 <SEP> <tb> <SEP> 2 <SEP> 6.0 <SEP> x <SEP> 108 <SEP> <tb> <SEP> 5 <SEP> 5.0 <SEP> x <SEP> 106 <SEP> <tb> <SEP> K <SEP> S <SEP> CN <SEP> 0.2 <SEP> 8.3 <SEP> x <SEP> 107 <tb> <SEP> 0.3 <SEP> 3.5 <SEP> x <SEP> 108 <tb> <SEP> 0.5 <SEP> 7.0 <SEP> x <SEP> 10' <tb> <SEP> 1.5 <SEP> 5.0 <SEP> x <SEP> 108 <tb> <SEP> 2 <SEP> 7.4 <SEP> x <SEP> 107 <SEP> <tb> <SEP> 0.5 <SEP> 1.4 <SEP> x <SEP> 108 <SEP> <tb> Urea <SEP> 2 <SEP> 1.8 <SEP> x <SEP> 108 <tb> <SEP> Guanidine <SEP> 0.5 <SEP> 2.3 <SEP> x <SEP> 108 <tb> <SEP> hydrochloride <SEP> 2 <SEP> 1.2 <SEP> x <SEP> 108 <SEP> <tb> The present invention thus provided has achieved about 4-fold increase in yield as compared with the conventional extraction/recovery method. As a result, the prevent invention makes it possible to practice, on a commercial level, those gene recombination techniques which use Escherichia coli and the like as hosts and which have been so far unsuccessful in achieving satisfactory production efficiency for reasons of intracellular product accumulation.

Claims: Claims 1. A method of producing heterologous proteins by cultivating a genetically engineered transformant capable' of producing a heterologous protein and recovering the - thus-produced heterologous protein, which is characterized in that, in a step after removal of the outer celt wall from the transformant with the heterologoui protein produced contained:therein, the heterologous protein is solubilized with at least one ion selected from among the chloride ion, thiocyanate ion and nitrate ion each derived from a dissociable salt. 2. A method of producing heterologous proteins as claimed in Claim 1, wherein the salt is an alkali metal salt or an alkaline earth metal salt. 3. A method of producing heterologous proteins as claimed in Claim 1. wherein the salt is at least one salt selected from among alkaline earth metal chlorides, alkali metal thiocyanates and alkali metal nitrates. 4. A method of producing heterologous proteins as claimed in Claim 1, wherein the salt is at least one salt selected from among magnesium chloride, potassium thiocyanate, sodium thiocyanate and sodium nitrate. 5. A method of producing heterologous proteins as claimed in Claim 1, wherein a chloride ion-releasing dissociable salt and/or a nitrate ion-releasing dissociable salt is used in a concentration of 0.15-6 M. 6. A method of producing heterologous proetins as claimed in Claim 1 wherein a thiocyanate 1 dissociable salt is used in a concentration of 0.25-1.5 M.

Inventors: ARIMURA, HIROFUMI, HIRAMATSU, RYUJI, ISHIKAWA, HIDEYUKI, NAGAI, MASANORI, TANABE, YOSHIZUMI, WATANABE, HIRONOBU
Applicants: THE GREEN CROSS CORPORATION
Application year: 1985
Main classification: C12P21
IPC codes: C12P21, C12N1